Overview
Adam Fine is Founder & Managing Partner at Windham Capital Partners, a New York City growth equity firm founded in 2006 that focuses on medical technology and digital health [2][3]. Fine holds board positions at Andros [1], NeuSpera Medical Inc. [7], and serves as board observer at ChromaCode, Inc. [4], Upward Health [5], Personal Genome Diagnostics [8], Cureatr [9], and Cartiva, Inc. [10]. Fine earned an MBA in Finance from New York University [11] and a BA in International Relations from Boston University [12].
Profile introduction
Founded in 2006, Windham Capital Partners is a New York City growth equity firm, working at the intersection of medical technology and digital health. We invest in transformative companies and teams improving clinical outcomes, expanding access to quality healthcare and creating more efficiencies in healthcare. With deep expertise and a far-reaching network across medical devices, digital health / software, and life sciences, Windham partners with visionary founders and entrepreneurs to develop and elevate the standard of healthcare. Supported by a network of industry experts, including an Adv…
Career history
- Founder & Managing PartnerJan 2006 to presentWindham Capital Partners
- Board ObserverAug 2019 to presentChromaCode, Inc.
- Board ObserverDec 2017 to presentUpward Health (formerly BehaveCare)
- Board MemberNov 2017 to presentAndros
- Board MemberOct 2017 to presentNeuSpera Medical Inc.
- Board ObserverOct 2015 to presentPersonal Genome Diagnostics
- Board ObserverJun 2015 to presentCureatr
- Board ObserverMay 2015 to presentCartiva, Inc.
Education
MBA, Finance2000 - 2002New York University
BA, International Relations1991 - 1995Boston University
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.